Lannett Company, Inc. (NYSE:LCI)‘s stock had its “market perform” rating restated by equities researchers at Oppenheimer in a research report issued on Thursday, MarketBeat.Com reports.

Several institutional investors recently made changes to their positions in LCI. California State Teachers Retirement System increased its position in shares of Lannett Company by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 49,119 shares of the company’s stock worth $1,971,000 after buying an additional 775 shares in the last quarter. Nationwide Fund Advisors increased its position in shares of Lannett Company by 54.3% in the fourth quarter. Nationwide Fund Advisors now owns 83,580 shares of the company’s stock worth $3,353,000 after buying an additional 29,398 shares in the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of Lannett Company by 2.5% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 38,730 shares of the company’s stock worth $1,554,000 after buying an additional 936 shares in the last quarter. Thompson Siegel & Walmsley LLC increased its position in shares of Lannett Company by 20.2% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 706,461 shares of the company’s stock worth $28,343,000 after buying an additional 118,784 shares in the last quarter. Finally, Cambiar Investors LLC increased its position in shares of Lannett Company by 18.5% in the fourth quarter. Cambiar Investors LLC now owns 779,866 shares of the company’s stock worth $31,288,000 after buying an additional 121,858 shares in the last quarter.

Lannett Company (NYSE:LCI) traded up 2.47% during trading on Thursday, reaching $26.14. 1,685,009 shares of the company were exchanged. The firm has a market capitalization of $954.82 million and a PE ratio of 6.55. The stock has a 50 day moving average price of $36.48 and a 200 day moving average price of $44.95. Lannett Company has a 12 month low of $23.88 and a 12 month high of $72.44.

Lannett Company (NYSE:LCI) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.99 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.89 by $0.10. The business had revenue of $106.40 million for the quarter, compared to analyst estimates of $103.90 million. During the same quarter in the prior year, the company earned $0.94 EPS. The firm’s revenue for the quarter was up 14.0% on a year-over-year basis. On average, analysts expect that Lannett Company will post $3.76 EPS for the current fiscal year.

A number of other equities analysts also recently commented on LCI. Zacks Investment Research downgraded shares of Lannett Company from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 3rd. Craig Hallum downgraded shares of Lannett Company from a “buy” rating to a “hold” rating in a research report on Thursday, November 5th. Susquehanna upped their price objective on shares of Lannett Company from $48.00 to $50.00 and gave the stock a “positive” rating in a research report on Tuesday, December 22nd. Finally, Raymond James cut their price objective on shares of Lannett Company to $45.00 in a research report on Wednesday, January 27th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $54.73.

Lannett Company, Inc. develops, manufactures, packages, markets and distributes solid oral (NYSE:LCI), extended release, topical and oral solution finished dosage forms of drugs. The Company also manufactures active pharmaceutical ingredients through its Cody Laboratories, Inc. (Cody Labs) subsidiary. The Company operates pharmaceutical manufacturing plants in Philadelphia, Pennsylvania and Cody, Wyoming. Customers of the Company’s pharmaceutical products include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, Governmental entities and health maintenance organizations. The Company’s products include Levothyroxine Sodium tablets, Digoxin tablets, Butalbital, Cocaine Topical Solution and Morphine Sulfate Oral Solution.

12 Month Chart for NYSE:LCI

Receive News & Ratings for Lannett Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.